Media Coverage

23 November 2022
Neil Clark speaks to Labiotech about Antimicrobial Resistance
18th November 2022
Bill Love speaks to Proactive Investors on addressing the Global Threat of superbugs and AMR
5th October 2022
Neil Clark speaks to StockBox Media on NTCD-M3
8 September 2022
Neil Clark & Shaun Claydon of Destiny Pharma: Significant progress in H1 will continue in 2022 & beyond – Vox Markets
19 July 2022
Destiny Pharma discusses positive update from FDA on their XF-73 nasal gel
19 July 2022
Destiny Pharma to trial nasal gel in breast surgery after ‘positive’ FDA feedback
12 May 2022
Destiny Pharma plc on its two lead infection prevention assets
12 May 2022
Destiny Pharma highlights new ‘landmark’ NTCD-M3 data
April 2022
Destiny Pharma discusses 2021 highlights and what is expected in 2022
March 2022
Destiny Pharma presentation at the Proactive One2One Virtual Forum
March 2022
Destiny Pharma podcast presentation to Vox Markets ‘New funds will progress two lead clinical assets towards Phase 3 trials’
February 2022
Destiny Pharma prepares to move to final study on novel XF-73 dermal formulation
December 2021
Destiny Pharma ‘2021 and beyond’ presentation to Vox Markets
December 2021
Destiny Pharma presentation at the Proactive One2One Investor Forum
November 2021
Professor Dale Gerding, a world leader in C. difficile infections speaks to Equity Development about the significant problem of CDI and how Destiny Pharma’s novel NTCD-M3 clinical programme can provide a breakthrough in patients’ treatment
November 2021
Destiny Pharma presentation on NTCD-M3 to the 9th Annual International C. diff Conference & Health Expo
October 2021
Alan Green talks to CEO Neil Clark
September 2021
Destiny Pharma presentation at the Proactive One2One Virtual Forum
August 2021
Destiny Pharma publish more evidence of surgery nasal gel effectiveness
July 2021
@VoiceAmericaTRN C. diff Spores and More radio programme – recorded 20th July at 1800 BST
July 2021
Destiny Pharma presentation at the Shares Investor Evening – 6th July 2021
June 2021
Destiny Pharma presentation at the Cenkos Growth and Innovation Forum – 8th June 2021
June 2021
Destiny Pharma consultant Professor Dale Gerding updates on recurrent C. difficile infections work
April 2021
Proactive Results Interview
April 2021
Developing Novel Medicines that Prevent Serious Infections
March 2021
Proactive Elevator Pitch

 

Video Archive